Cyclo Therapeutics, Inc. financial data

Symbol
CYTH, CYTHW on Nasdaq
Location
6714 Nw 16 Th Street, Suite B, Gainesville, FL
Fiscal year end
December 31
Latest financial report
10-K/A - Q4 2023 - Dec 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 61.1 % -30.6%
Quick Ratio 2.24 % -51%
Return On Equity 750 % -78.3%
Return On Assets -326 % +21.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.8M shares +26.6%
Common Stock, Shares, Outstanding 28.8M shares +48.6%
Entity Public Float 17.2M USD +17.2%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 28.7M shares +77.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16M USD +20.8%
Costs and Expenses 25.5M USD +26.7%
Operating Income (Loss) -24.7M USD -27.3%
Nonoperating Income (Expense) -111K USD +32.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24.8M USD -27.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.8M USD -27.9%
Earnings Per Share, Basic -1 USD/shares -102%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 928K USD -48.5%
Accounts Receivable, after Allowance for Credit Loss, Current 188K USD -38.2%
Inventory, Net 236K USD +12.6%
Assets, Current 3.26M USD -40.9%
Property, Plant and Equipment, Net 20K USD -50.9%
Operating Lease, Right-of-Use Asset 26.6K USD -40.6%
Assets 5.25M USD -6.13%
Accounts Payable, Current 5.02M USD
Liabilities, Current 18.7M USD +183%
Operating Lease, Liability, Noncurrent 7.14K USD -73.8%
Retained Earnings (Accumulated Deficit) -103M USD -31.7%
Stockholders' Equity Attributable to Parent -13.5M USD -1180%
Liabilities and Equity 5.25M USD -6.13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.18M USD -41.5%
Net Cash Provided by (Used in) Financing Activities -69.3K USD -102%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 250M shares +400%
Common Stock, Shares, Issued 28.8M shares +48.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.25M USD -895%
Interest Paid, Excluding Capitalized Interest, Operating Activities 756 USD -56.3%
Deferred Tax Assets, Valuation Allowance 24.8M USD +7.17%
Operating Lease, Liability 1.03M USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.98M USD -29%
Lessee, Operating Lease, Liability, to be Paid 1.04M USD
Property, Plant and Equipment, Gross 159K USD +1.54%
Operating Lease, Liability, Current 20.1K USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.6K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.02M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure -50%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.9K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.8K USD
Deferred Tax Assets, Operating Loss Carryforwards 12.6M USD +17.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 6.95M USD
Additional Paid in Capital 89.5M USD +16%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.18K USD -54.8%
Deferred Tax Assets, Net of Valuation Allowance 230K USD +5650%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%